Filing Analysis
Acrivon Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results and business updates for the period ending June 30, 2026.
📋 Key Facts
- The filing is a standard earnings release under Item 2.02.
- Reports financial results for the quarter ended June 30, 2026.
- Includes business updates via Exhibit 99.1.
Acrivon Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. Key outcomes included the election of two Class I directors, the ratification of PwC as the independent auditor, and the approval of an amended equity incentive plan.
📋 Key Facts
- Stockholders approved the Amended and Restated 2022 Equity Incentive Plan, increasing the share reserve by 3,000,000 shares for a total of 8,606,723 shares.
- The equity plan includes an automatic annual increase (evergreen provision) of 5% of fully diluted shares through 2032.
- Michael Tomsicek and Charles Baum were elected as Class I Directors until the 2029 Annual Meeting.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Quorum was established with 73.21% of outstanding shares present or represented by proxy.
Acrivon Therapeutics reported its financial results for the first quarter ended March 31, 2026, and provided a general business update. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2026, on May 13, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The company is an emerging growth company as defined by the SEC.
- The filing includes Exhibit 99.1, which is the press release detailing financial performance.
Acrivon Therapeutics reported its Q4 and full-year 2025 financial results and provided a clinical update on its ACR-368 Phase 2b study. The company is initiating a new registrational-intent arm for endometrial cancer and has successfully completed an exploratory arm involving gemcitabine sensitization.
📋 Key Facts
- Announced financial results for the fourth quarter and full year ended December 31, 2025.
- Initiated Arm 4 of the registrational-intent ACR-368 Phase 2b study for serous type endometrial cancer subjects with ≤2 prior lines of therapy.
- Completed exploratory Arm 2 of the study, which treated biomarker-negative (BM-) subjects with ACR-368 and ultra-low dose gemcitabine (ULDG) sensitization.
- Reported that Arm 2 objectives were achieved, supporting ULDG's role in ACR-368 efficacy for BM- subjects with a favorable tolerability profile.
Acrivon Therapeutics terminated its companion diagnostic agreement with Akoya Biosciences to bring ACR-368 OncoSignature testing in-house. The transition follows the completion of Acrivon's own CLIA-certified laboratory, granting the company full control over its diagnostic development and commercialization rights.
📋 Key Facts
- On February 25, 2026, the company terminated the OncoSignature Companion Diagnostic Agreement with Akoya Biosciences (a Quanterix subsidiary).
- The termination involves no financial payments or penalties from either party.
- Acrivon has established its own internally-owned and operated CLIA-certified laboratory in Watertown, Massachusetts.
- Quanterix will continue to provide testing support during a transition period for the ongoing registrational-intent Phase 2b study.
- Acrivon retains full development and commercialization rights to the proprietary ACR-368 OncoSignature test.
Acrivon Therapeutics hosted a Key Opinion Leader (KOL) panel at the ESGO Congress to discuss interim Phase 2b clinical data for ACR-368. The presentation focused on the drug's registrational-intent trial and its potential to treat endometrial cancer, specifically the serous sub-type.
📋 Key Facts
- The KOL panel took place on February 27, 2026, at the European Society of Gynecological Oncology (ESGO) Congress in Copenhagen.
- Discussion included interim clinical data from the ACR-368 Phase 2b registrational-intent trial.
- The company is targeting unmet patient needs in endometrial cancer, particularly the serous sub-type.
- Presentation slides were filed as Exhibit 99.1.
Acrivon Therapeutics hosted a corporate webcast on January 8, 2026, providing clinical data updates for ACR-368 and initial clinical data for ACR-2316. The company released a presentation via its website as part of Regulation FD disclosure.
📋 Key Facts
- Hosted a corporate webcast/conference call on January 8, 2026, from 8:30 a.m. to 9:00 a.m. ET.
- Released 'January 8, 2026 Data Update' via the company website (ir.acrivon.com).
- The update includes clinical data for ACR-368 and initial clinical data for program ACR-2316.
Acrivon Therapeutics reported positive clinical data updates for its lead programs ACR-368 and ACR-2316, alongside a cash runway extending into Q2 2027. The company is expanding its clinical footprint into the EU and advancing new candidates through its AP3 platform.
🚩 Red Flags
- Preliminary financial data is unaudited and subject to material change.
📋 Key Facts
- Preliminary unaudited cash, cash equivalents, and investments: ~$119 million as of Dec 31, 2025.
- Cash runway expected to fund operations into Q2 2027.
- ACR-368 Phase 2b (Arm 1) showed an ORR of 39% in BM+ subjects and 44% in subjects with ≤2 prior lines of therapy.
- ACR-368 Arm 3 to focus exclusively on serous cancer patients; EU clinical trial application submitted for expansion into Germany, Italy, France, and Spain.
- ACR-2316 Phase 1 showed tumor shrinkage in 9 out of 20 evaluable patients at the 120 mg dose level or above.
- New development candidate ACR-6840 (CDK11 inhibitor) nominated; IND submission anticipated in Q4 2026.
Acrivon Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025, and provide a business update via press release.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes Exhibit 99.1 containing the earnings press release and business updates.
- Company is an emerging growth company.
Acrivon Therapeutics issued an 8-K to disclose a corporate presentation update containing new preclinical data for its clinical candidates ACR-368 and ACR-2316. The update highlights positive synergy with immune checkpoint inhibitors in mouse models, showing complete tumor regression and immune memory.
📋 Key Facts
- Released updated Corporate Presentation via website on September 5, 2025.
- Reported follow-up syngeneic mouse model data for ACR-368 and ACR-2316.
- Observed continued complete tumor regression and immune memory in multiple rounds of tumor implantations over nearly one year.
- Updated pipeline overview to include the all-comer ACR-368 + ULDG ARM 3 of the ongoing ACR-368-201 trial.
- Highlighted capabilities of the Generative Phosphoproteomics AP3 platform for novel drug design.
Acrivon Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results and business updates for the period ended June 30, 2025.
📋 Key Facts
- Report date: August 13, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes a press release as Exhibit 99.1 containing financial results and business updates.
- The company is an emerging growth company.
Acrivon Therapeutics held its 2025 annual meeting of stockholders on June 13, 2025. The meeting resulted in the election of three Class III directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 13, 2025.
- Quorum represented 94.59% of outstanding shares (29,659,010 shares).
- Peter Blume-Jensen, M.D., Ph.D., Derek DiRocco, Ph.D., and Santhosh Palani, Ph.D., C.F.A. were elected to the Board as Class III Directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
Acrivon Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025, and provided general business updates via a press release.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an emerging growth company
Acrivon Therapeutics, Inc. announced the appointment of Mansoor Raza Mirza, M.D., as the new Chief Medical Officer, effective April 9, 2025.
📋 Key Facts
- Appointment of Mansoor Raza Mirza, M.D. as Chief Medical Officer.
- Effective date of appointment is April 9, 2025.
- The filing was signed by CEO Peter Blume-Jensen on April 7, 2025.
Acrivon Therapeutics, Inc. filed an 8-K to furnish its press release announcing financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 27, 2025
- Reporting period: Q4 and Full Year ended December 31, 2024
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure)
- Financial results are provided via Exhibit 99.1
Acrivon Therapeutics reported preliminary clinical data for its lead asset ACR-368, showing significant efficacy in Oncosignature-positive (BM+) endometrial cancer patients. The company also announced the strategic deprioritization of ovarian and bladder cancer programs to focus resources on endometrial cancer and its second asset, ACR-2316.
🚩 Red Flags
- Strategic pivot/deprioritization of two major indications (ovarian and bladder cancer) indicates resource reallocation due to unmet clinical benchmarks.
- Preliminary financial data is subject to change as FY2024 statements are not yet finalized.
📋 Key Facts
- Preliminary cash/short-term investments as of Dec 31, 2024: ~$184.6 million.
- ACR-368 in BM+ endometrial cancer (monotherapy): Confirmed ORR of 35% and DCR of 80%.
- In refractory BM+ patients (no response to last line), ACR-368 showed 33% ORR and 75% DCR.
- ACR-368 + LDG combination in BM- patients: Confirmed ORR of ~13%.
- Deprioritized ovarian cancer and bladder cancer programs due to low clinical bar/enrollment challenges.
- ACR-2316 Phase 1 trial shows dose proportionality and initial signs of clinical activity (one patient with significant lesion reduction).
- Cash runway expected to extend into 2027.
Acrivon Therapeutics announced a leadership transition in its finance department, involving the departure of CFO Rasmus Holm-Jorgensen and the appointment of Adam Levy, PhD, MBA, as the new CFO and Principal Financial Officer effective April 1, 2025.
🚩 Red Flags
- None identified; the departure is characterized as non-dispute related.
📋 Key Facts
- Rasmus Holm-Jorgensen is stepping down as CFO effective April 1, 2025, for personal reasons to pursue an opportunity in Europe.
- The company stated the departure is not due to any disagreement regarding operations, finances, policies, or practices.
- Adam Levy, PhD, MBA, appointed as CFO and Principal Financial Officer effective April 1, 2025.
- Dr. Levy's compensation includes a $490,000 annual salary and a 40% performance bonus eligibility.
- Dr. Levy will receive an equity grant of 35,209 stock options vesting over 4 years.
Acrivon Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ending September 30, 2024. The filing serves as a standard mechanism to provide business updates and financial results to shareholders.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The company issued a press release (Exhibit 99.1) containing financial results and business updates.
- Company is classified as an 'Emerging Growth Company'.
Acrivon Therapeutics announced the commencement of initial patient dosing in its Phase 1 clinical trial for ACR-2316, a selective WEE1/PKMYT1 inhibitor. The company expects to release initial clinical data from this monotherapy dose optimization trial in the second half of 2025.
📋 Key Facts
- First patient has been dosed in the Phase 1 clinical trial for ACR-2316.
- ACR-2316 is a selective WEE1/PKMYT1 inhibitor designed using AP3 technology.
- The trial targets patients with selected solid tumors.
- Initial clinical data from the monotherapy dose optimization trial is expected in H2 2025.
Acrivon Therapeutics reported positive Phase 2 clinical data for ACR-368 in endometrial cancer patients, demonstrating a 62.5% objective response rate in OncoSignature-positive subjects. The company also announced FDA clearance for its next candidate, ACR-2316, with first-in-human dosing expected in Q4 2024.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- ACR-368 Phase 2 data showed a 62.5% objective response rate (ORR) in OncoSignature-positive patients who had progressed on prior anti-PD-1 therapy.
- The AP3-based OncoSignature assay achieved statistical significance (p-value = 0.009) in segregating responders from non-responders.
- FDA cleared the IND for ACR-2316; first-in-human dosing is expected in Q4 2024.
- As of June 30, 2024, the company held $220.4 million in cash, cash equivalents, and investments.
- Cash runway is expected to extend into the second half of 2026.
Acrivon Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided general business updates via a press release.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes Exhibit 99.1 containing the press release with financial results and business updates.
- Company is an emerging growth company.
Acrivon Therapeutics held its 2024 annual meeting of stockholders on June 20, 2024. The meeting resulted in the election of three Class II directors and the ratification of PricewaterhouseCoopers LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 20, 2024.
- Quorum represented 88.81% of outstanding shares (27,422,027 shares).
- Kristina Masson, Ph.D., M.B.A; Sharon Shacham, Ph.D., M.B.A.; and Ivana Magovčević-Liebisch, Ph.D., J.D. were elected to Class II Director positions until 2027.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Acrivon Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended March 31, 2024. The filing serves as a standard disclosure of financial results and business updates.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: Quarter ended March 31, 2024
- The company is an emerging growth company
- Filing includes Exhibit 99.1 (Press Release)
Acrivon Therapeutics reported preliminary cash balances and announced positive Phase 2b clinical data for its ACR-368 asset. The company also highlighted a significant liquidity runway extending into the second half of 2026 following a recent private placement.
🚩 Red Flags
- Financial statements for the period ending March 31, 2024, are not yet finalized; preliminary figures are subject to change.
📋 Key Facts
- Preliminary cash, cash equivalents, and short-term investments: ~$110 million as of March 31, 2024.
- Pro forma cash position (including April 9 private placement proceeds): ~$234 million.
- Phase 2b clinical data for ACR-368 showed a 50% Objective Response Rate (ORR) in OncoSignature-positive patients (n=10).
- OncoSignature-negative arm showed 0% ORR but 8 of 16 patients achieved stable disease when combined with ultra-low dose gemcitabine.
- The company expects current cash to fund operations into the second half of 2026.
Acrivon Therapeutics announced a $130 million private placement involving the issuance of common stock and pre-funded warrants to institutional investors. The proceeds are intended to fund R&D for its clinical pipeline and platform technologies.
🚩 Red Flags
- Significant potential dilution from the issuance of over 8.2 million shares and 7 million pre-funded warrants.
- Pre-funded warrants with extremely low exercise prices ($0.001) function similarly to common stock, increasing immediate dilutive pressure.
- Registration rights agreement includes liquidated damages provisions for registration failures.
📋 Key Facts
- Total gross proceeds: Approximately $130 million.
- Securities issued: 8,235,000 shares of common stock at $8.50 per share and up to 7,060,000 pre-funded warrants at $8.499 per warrant.
- Pre-funded warrants have an exercise price of $0.001 per share and no expiration date.
- Jefferies LLC acted as the sole placement agent.
- The company agreed to a registration statement for resale by May 11, 2024.
- Includes a board observer right for a lead purchaser if they own at least 50% of their warrants/shares.
Acrivon Therapeutics, Inc. filed an 8-K to furnish its press release announcing financial results for the fourth quarter and full year ended December 31, 2023.
📋 Key Facts
- Report date: March 28, 2024
- Reporting period: Fourth quarter and full year ended December 31, 2023
- Company is an emerging growth company
- The filing includes Exhibit 99.1 (Press Release)
Acrivon Therapeutics, Inc. announced the appointment of Santhosh Palani, Ph.D., CFA, to its Board of Directors effective March 4, 2024.
📋 Key Facts
- Santhosh Palani, Ph.D., CFA, appointed as a director on March 1, 2024 (effective March 4, 2024).
- Director will receive a stock option grant of 32,500 shares vesting over 3 years in monthly installments.
- Compensation includes cash and indemnification per the Company's standard non-employee director arrangements.
Acrivon Therapeutics, Inc. announced the appointment of Ivana Magovcevic-Liebisch, Ph.D., J.D., to its Board of Directors, effective February 8, 2024.
📋 Key Facts
- Appointment of Ivana Magovcevic-Liebisch, Ph.D., J.D. as a director effective Feb 8, 2024.
- Director will receive a stock option grant of 32,500 shares vesting over 3 years in monthly installments.
- Compensation includes cash and standard indemnification agreements per the Company's Definitive Proxy Statement filed May 1, 2023.
Acrivon Therapeutics announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference and released an updated corporate presentation. The filing includes a confirmation of the company's projected cash runway extending into the second half of 2025.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Company to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, at 2:15 PM ET.
- Updated corporate presentation released as Exhibit 99.1.
- Management confirmed a projected cash runway into the second half of 2025.